Amplifier Therapeutics, a Swedish clinical-stage drug development company, raised additional funding in Series A round.
RA Capital Management and Future Ventures joined the Amplifier Series A financing led by Cambrian. This new funding brings Amplifier’s Series A to $33.25m, enabling the company to significantly accelerate its research and development efforts.
The Cambrian Bio pipeline company also announced the dosing of the first patient in its Phase 1B clinical trial investigating ATX-304, a peripherally restricted pan-AMPK activator being developed for the treatment of cardiometabolic diseases. The Phase 1B trial is an 8-week, double-blind, randomized placebo-controlled study in prediabetic, overweight or obese subjects, being conducted in the European Union. The study will focus primarily on the safety and pharmacokinetics of ATX-304 and also will include exploratory outcomes measuring its effect on metabolic parameters and muscle.
Led by James Hall, CEO, Amplifier TX AB, doing business as Amplifier Therapeutics, is a biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat diseases associated with aging including metabolic conditions, cardiovascular diseases, kidney diseases, and cancer. Amplifier Therapeutics’ wholly-owned subsidiary, Betagenon AB, serves as Sponsor for the clinical trial. ATX-304 was discovered by three leading AMPK researchers: Helena Edlund, Thomas Edlund, and the late Olof Karlsson.
In 2023, Amplifier Therapeutics became the third of Cambrian’s pipeline companies to emerge from stealth mode.
FinSMEs
18/10/2023